Filed by Onconetix, Inc.
Pursuant to Rule 425 under the Securities Act
of 1933
and deemed filed pursuant to Rule 14a-6(b)
under the Securities Exchange Act of 1934
Subject Company: Onconetix, Inc.
Commission File No.: 001-41294
Date: September 14, 2026
Onconetix Provides Strategic Bridge Financing
to Realbotix LLC in Support of Pending Acquisition
Initial Advance of $2.5 Million to Realbotix
LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing
of Pending Acquisition
CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE)
-- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has provided a strategic
bridge financing facility of up to $5,000,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending
acquisition, to support Realbotix’s growth and working capital needs while the parties advance toward closing of the acquisition.
The financing was provided in connection with the Share Exchange Agreement between the two companies, announced on February 12, 2026.
The facility provides for an aggregate principal
amount of up to $5,000,000, with an initial advance of $2,500,000.
The facility is non-interest bearing prior to
the closing of the Share Exchange Agreement. Upon closing of the acquisition, the facility and all obligations thereunder will be automatically
cancelled and discharged in full. In addition, the cash required at closing of the acquisitions will be reduced by the total principal
advanced under the facility plus an additional $500,000. If the Share Exchange Agreement is terminated, interest accrues at 12% per annum
from the date of termination. A description of the Note is included in Onconetix’s Current Report on Form 8-K filed with the SEC
on [DATE], 2026. The full text of the Note is filed as an exhibit to that report and is available at www.sec.gov.
As previously announced on February 12, 2026,
Onconetix entered into the Share Exchange Agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in
an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is subject to Onconetix shareholder
approval, required regulatory approvals, and other closing conditions.
This communication is being provided for informational
purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage
biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®,
an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under
the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more
information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of
Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops
AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States,
Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information,
visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between
Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”)
to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include
a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and
Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared
effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed
transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that
Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS
OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED
TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE,
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus,
as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available,
at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not
be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective
directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed
transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s
transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed
from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other
persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction
and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction
or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available,
at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes
only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or
the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt
from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and
“intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities
that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances
that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed
transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including
the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related
to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that
may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed
transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are
not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or
take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention
from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may
affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed
with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s
forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth
herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
3
